To: Jibacoa who wrote (586 ) 11/22/2006 12:13:35 PM From: Jibacoa Read Replies (1) | Respond to INGN is doing a good job trying to keep the stock above the $4.50 level, but in spite of all the recent news the short sellers seem to keep giving them a hard time.<g>Introgen Therapeutics Receives Broad Patent for Purified Adenoviral Compositions has been awarded U.S. Patent No. 7,125,706, titled "An Improved Method for the Production and Purification of Adenoviral Vectors." This patent complements two previously issued U.S. patents in Introgen's intellectual property portfolio directed to the production of adenoviral vectors. "With this patent, we have complemented and enhanced the coverage of Introgen's previously announced U.S. patents that cover the commercial production of adenoviruses in general, and without regard to the gene they carry, if any, or their use." it covers adenovirus of commercial scale quantity and purity, regardless of whether the adenovirus is used as a delivery system for therapeutic genes, used directly as a therapeutic agent, used as a vaccine or vaccine component or simply used for research and development purposes. bigcharts.marketwatch.com
